Kieuhoa T. Vo

Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

Kieuhoa T. Vo, Katherine K. Matthay, John Neuhaus et al. · Journal of Clinical Oncology · 2014 · 217 citations · Full text

Medicine, Oncology, Pediatrics +16

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group

David S. Shulman, Kelly Klega, Alma Imamović et al. · British Journal of Cancer · 2018 · 137 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

Kelly C. Goldsmith, Julie R. Park, Kimberly Kayser et al. · Nature Medicine · 2023 · 125 citations · Full text

Medicine, Oncology, Pharmacology +10

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

Steven G. DuBois, Meaghan Granger, Susan Groshen et al. · Journal of Clinical Oncology · 2021 · 85 citations · Full text

Medicine, Oncology, Pharmacotherapy +7

Identification of patient subgroups with markedly disparate rates of <i>MYCN</i> amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project

Daria Thompson, Kieuhoa T. Vo, Wendy B. London et al. · Cancer · 2015 · 79 citations · Full text

Medicine, Oncology, Pathology +17